You are here

Study Evaluating Temsirolimus (CCI-779) In Breast Neoplasms

Last updated on February 22, 2019

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Breast Neoplasms
Sex
Female
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Postmenopausal women with histologically confirmed, measurable locally advanced
disease or metastatic breast.

- Must be appropriate to receive endocrine therapy as treatment for advanced disease
(chemotherapy; prior adjuvant therapy with antiestrogens other than aromatase
inhibitors; prior adjuvant or first-line metastatic therapy with tamoxifen or
trastuzumab, are permitted).

- Women may either present with de novo advanced or metastatic cancer, or have had tumor
progression while receiving adjuvant tamoxifen or at any time after completing
adjuvant tamoxifen, or have had tumor progression while receiving first-line
metastatic therapy with tamoxifen.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients having known central nervous system (CNS) metastases.

- Prior therapy with Temsirolimus (CCI-779) or aromatase inhibitors.

- Tamoxifen, or other hormonal therapy, in the metastatic or adjuvant setting within 1
week prior to day 1 of treatment on study.

NCT00062751
Pfizer
Completed
Study Evaluating Temsirolimus (CCI-779) In Breast Neoplasms

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Breast Neoplasms
NCT00322517
Females
18+
Years
Multiple Sites
Breast Neoplasms, Stomach Neoplasms, Esophagogastric Junction Neoplasm, Non-small-cell Lung Carcinoma
NCT03284723
All Genders
18+
Years
Multiple Sites
Melanoma, Breast Neoplasms, Renal Cell Carcinoma, T-Cell Lymphoma, Non-Small-Cell Lung Carcinoma
NCT00043368
All Genders
18+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now